nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—FOLR1—epilepsy syndrome	0.171	0.404	CbGaD
Methotrexate—ATIC—epilepsy syndrome	0.129	0.306	CbGaD
Methotrexate—SLCO1A2—epilepsy syndrome	0.0541	0.128	CbGaD
Methotrexate—SLCO1C1—Phenytoin—epilepsy syndrome	0.0385	0.125	CbGbCtD
Methotrexate—AOX1—Zonisamide—epilepsy syndrome	0.03	0.0972	CbGbCtD
Methotrexate—ABCC2—epilepsy syndrome	0.0259	0.0613	CbGaD
Methotrexate—SLC16A1—Valproic Acid—epilepsy syndrome	0.0256	0.083	CbGbCtD
Methotrexate—ABCG2—epilepsy syndrome	0.0229	0.0542	CbGaD
Methotrexate—ABCC3—Phenobarbital—epilepsy syndrome	0.0216	0.0698	CbGbCtD
Methotrexate—ABCC2—Levetiracetam—epilepsy syndrome	0.0213	0.0691	CbGbCtD
Methotrexate—ABCC1—Phenobarbital—epilepsy syndrome	0.0132	0.0429	CbGbCtD
Methotrexate—SLC22A7—Valproic Acid—epilepsy syndrome	0.0126	0.0408	CbGbCtD
Methotrexate—ABCC2—Carbamazepine—epilepsy syndrome	0.0123	0.0397	CbGbCtD
Methotrexate—ALB—Oxcarbazepine—epilepsy syndrome	0.0122	0.0394	CbGbCtD
Methotrexate—ABCC2—Phenytoin—epilepsy syndrome	0.011	0.0356	CbGbCtD
Methotrexate—ALB—Fosphenytoin—epilepsy syndrome	0.0106	0.0344	CbGbCtD
Methotrexate—ALB—epilepsy syndrome	0.00997	0.0236	CbGaD
Methotrexate—ABCC2—Phenobarbital—epilepsy syndrome	0.0098	0.0317	CbGbCtD
Methotrexate—ALB—Clonazepam—epilepsy syndrome	0.00962	0.0311	CbGbCtD
Methotrexate—ABCB1—epilepsy syndrome	0.00952	0.0225	CbGaD
Methotrexate—ALB—Rufinamide—epilepsy syndrome	0.00784	0.0254	CbGbCtD
Methotrexate—SLC22A8—Valproic Acid—epilepsy syndrome	0.00769	0.0249	CbGbCtD
Methotrexate—SLC22A6—Acetazolamide—epilepsy syndrome	0.00717	0.0232	CbGbCtD
Methotrexate—ABCB1—Levetiracetam—epilepsy syndrome	0.00696	0.0225	CbGbCtD
Methotrexate—ALB—Phenytoin—epilepsy syndrome	0.00685	0.0222	CbGbCtD
Methotrexate—ALB—Propofol—epilepsy syndrome	0.00639	0.0207	CbGbCtD
Methotrexate—ALB—Diazepam—epilepsy syndrome	0.00579	0.0188	CbGbCtD
Methotrexate—SLC22A6—Valproic Acid—epilepsy syndrome	0.00536	0.0174	CbGbCtD
Methotrexate—ABCB1—Clobazam—epilepsy syndrome	0.00482	0.0156	CbGbCtD
Methotrexate—ABCB1—Lamotrigine—epilepsy syndrome	0.00464	0.015	CbGbCtD
Methotrexate—ABCB1—Carbamazepine—epilepsy syndrome	0.004	0.0129	CbGbCtD
Methotrexate—ABCB1—Phenytoin—epilepsy syndrome	0.00358	0.0116	CbGbCtD
Methotrexate—ABCB1—Phenobarbital—epilepsy syndrome	0.00319	0.0103	CbGbCtD
Methotrexate—ABCB1—Midazolam—epilepsy syndrome	0.00315	0.0102	CbGbCtD
Methotrexate—ABCB1—Diazepam—epilepsy syndrome	0.00303	0.00981	CbGbCtD
Methotrexate—ATIC—forelimb—epilepsy syndrome	0.00216	0.0543	CbGeAlD
Methotrexate—SLC19A1—tongue—epilepsy syndrome	0.00179	0.0451	CbGeAlD
Methotrexate—ATIC—ganglion—epilepsy syndrome	0.00117	0.0294	CbGeAlD
Methotrexate—Pemetrexed—ATIC—epilepsy syndrome	0.00109	0.424	CrCbGaD
Methotrexate—SLCO1C1—ganglion—epilepsy syndrome	0.000969	0.0244	CbGeAlD
Methotrexate—Tetrahydrofolic acid—ATIC—epilepsy syndrome	0.000878	0.342	CrCbGaD
Methotrexate—MTHFR—ganglion—epilepsy syndrome	0.000866	0.0218	CbGeAlD
Methotrexate—TYMS—L-Glutamine—Vigabatrin—epilepsy syndrome	0.000573	0.378	CbGdCrCtD
Methotrexate—GGH—telencephalon—epilepsy syndrome	0.000529	0.0133	CbGeAlD
Methotrexate—ATIC—brainstem—epilepsy syndrome	0.000507	0.0128	CbGeAlD
Methotrexate—FOLR1—head—epilepsy syndrome	0.000496	0.0125	CbGeAlD
Methotrexate—ATIC—forebrain—epilepsy syndrome	0.000489	0.0123	CbGeAlD
Methotrexate—FOLR1—central nervous system—epilepsy syndrome	0.000452	0.0114	CbGeAlD
Methotrexate—ATIC—telencephalon—epilepsy syndrome	0.00045	0.0113	CbGeAlD
Methotrexate—FOLR1—cerebellum—epilepsy syndrome	0.000442	0.0111	CbGeAlD
Methotrexate—SLC19A1—head—epilepsy syndrome	0.000435	0.0109	CbGeAlD
Methotrexate—GGH—medulla oblongata—epilepsy syndrome	0.000416	0.0105	CbGeAlD
Methotrexate—SLC19A1—nervous system—epilepsy syndrome	0.000412	0.0104	CbGeAlD
Methotrexate—SLCO1C1—forebrain—epilepsy syndrome	0.000407	0.0102	CbGeAlD
Methotrexate—SLC19A1—central nervous system—epilepsy syndrome	0.000397	0.00999	CbGeAlD
Methotrexate—DHFR—Niclosamide—Clonazepam—epilepsy syndrome	0.000391	0.258	CbGdCrCtD
Methotrexate—SLC19A1—cerebellum—epilepsy syndrome	0.000388	0.00976	CbGeAlD
Methotrexate—GGH—midbrain—epilepsy syndrome	0.00038	0.00956	CbGeAlD
Methotrexate—SLC46A1—spinal cord—epilepsy syndrome	0.000377	0.00949	CbGeAlD
Methotrexate—SLCO1C1—telencephalon—epilepsy syndrome	0.000374	0.00942	CbGeAlD
Methotrexate—GGH—spinal cord—epilepsy syndrome	0.000371	0.00933	CbGeAlD
Methotrexate—FPGS—medulla oblongata—epilepsy syndrome	0.000365	0.0092	CbGeAlD
Methotrexate—MTHFR—forebrain—epilepsy syndrome	0.000363	0.00915	CbGeAlD
Methotrexate—FOLR1—brain—epilepsy syndrome	0.000359	0.00904	CbGeAlD
Methotrexate—SLC46A1—head—epilepsy syndrome	0.000335	0.00843	CbGeAlD
Methotrexate—MTHFR—telencephalon—epilepsy syndrome	0.000334	0.00842	CbGeAlD
Methotrexate—GGH—head—epilepsy syndrome	0.000329	0.00829	CbGeAlD
Methotrexate—FPGS—spinal cord—epilepsy syndrome	0.000326	0.0082	CbGeAlD
Methotrexate—ATIC—midbrain—epilepsy syndrome	0.000323	0.00813	CbGeAlD
Methotrexate—SLC46A1—nervous system—epilepsy syndrome	0.000317	0.00799	CbGeAlD
Methotrexate—PGD—forebrain—epilepsy syndrome	0.000316	0.00795	CbGeAlD
Methotrexate—ATIC—spinal cord—epilepsy syndrome	0.000315	0.00793	CbGeAlD
Methotrexate—SLC19A1—brain—epilepsy syndrome	0.000315	0.00793	CbGeAlD
Methotrexate—GGH—nervous system—epilepsy syndrome	0.000312	0.00786	CbGeAlD
Methotrexate—SLC46A1—central nervous system—epilepsy syndrome	0.000306	0.0077	CbGeAlD
Methotrexate—TYMS—telencephalon—epilepsy syndrome	0.000305	0.00768	CbGeAlD
Methotrexate—DHFR—telencephalon—epilepsy syndrome	0.000302	0.0076	CbGeAlD
Methotrexate—GGH—central nervous system—epilepsy syndrome	0.000301	0.00757	CbGeAlD
Methotrexate—SLC46A1—cerebellum—epilepsy syndrome	0.000299	0.00752	CbGeAlD
Methotrexate—GGH—cerebellum—epilepsy syndrome	0.000294	0.0074	CbGeAlD
Methotrexate—PGD—telencephalon—epilepsy syndrome	0.00029	0.00731	CbGeAlD
Methotrexate—FPGS—head—epilepsy syndrome	0.00029	0.00729	CbGeAlD
Methotrexate—ATIC—head—epilepsy syndrome	0.00028	0.00705	CbGeAlD
Methotrexate—FPGS—nervous system—epilepsy syndrome	0.000275	0.00691	CbGeAlD
Methotrexate—Leucovorin—ABCC2—epilepsy syndrome	0.000273	0.106	CrCbGaD
Methotrexate—SLC16A1—telencephalon—epilepsy syndrome	0.000271	0.00683	CbGeAlD
Methotrexate—SLCO1C1—midbrain—epilepsy syndrome	0.000269	0.00676	CbGeAlD
Methotrexate—ATIC—nervous system—epilepsy syndrome	0.000265	0.00669	CbGeAlD
Methotrexate—FPGS—central nervous system—epilepsy syndrome	0.000264	0.00666	CbGeAlD
Methotrexate—SLCO1C1—spinal cord—epilepsy syndrome	0.000262	0.0066	CbGeAlD
Methotrexate—SLCO3A1—medulla oblongata—epilepsy syndrome	0.000258	0.00651	CbGeAlD
Methotrexate—FPGS—cerebellum—epilepsy syndrome	0.000258	0.0065	CbGeAlD
Methotrexate—ATIC—central nervous system—epilepsy syndrome	0.000256	0.00644	CbGeAlD
Methotrexate—ATIC—cerebellum—epilepsy syndrome	0.00025	0.00629	CbGeAlD
Methotrexate—ABCC10—telencephalon—epilepsy syndrome	0.000249	0.00627	CbGeAlD
Methotrexate—SLC46A1—brain—epilepsy syndrome	0.000243	0.00611	CbGeAlD
Methotrexate—GGH—brain—epilepsy syndrome	0.000239	0.00601	CbGeAlD
Methotrexate—DHFR—medulla oblongata—epilepsy syndrome	0.000237	0.00597	CbGeAlD
Methotrexate—SLCO3A1—midbrain—epilepsy syndrome	0.000236	0.00595	CbGeAlD
Methotrexate—SLCO1A2—forebrain—epilepsy syndrome	0.000233	0.00588	CbGeAlD
Methotrexate—SLCO1C1—head—epilepsy syndrome	0.000233	0.00586	CbGeAlD
Methotrexate—SLCO3A1—spinal cord—epilepsy syndrome	0.00023	0.0058	CbGeAlD
Methotrexate—PGD—medulla oblongata—epilepsy syndrome	0.000228	0.00574	CbGeAlD
Methotrexate—ABCC4—forebrain—epilepsy syndrome	0.000225	0.00565	CbGeAlD
Methotrexate—SLCO1C1—nervous system—epilepsy syndrome	0.000221	0.00556	CbGeAlD
Methotrexate—TYMS—midbrain—epilepsy syndrome	0.000219	0.00552	CbGeAlD
Methotrexate—DHFR—midbrain—epilepsy syndrome	0.000217	0.00546	CbGeAlD
Methotrexate—SLCO1A2—telencephalon—epilepsy syndrome	0.000215	0.0054	CbGeAlD
Methotrexate—SLC16A1—medulla oblongata—epilepsy syndrome	0.000213	0.00536	CbGeAlD
Methotrexate—SLCO1C1—central nervous system—epilepsy syndrome	0.000213	0.00535	CbGeAlD
Methotrexate—DHFR—spinal cord—epilepsy syndrome	0.000212	0.00533	CbGeAlD
Methotrexate—FPGS—brain—epilepsy syndrome	0.00021	0.00528	CbGeAlD
Methotrexate—PGD—midbrain—epilepsy syndrome	0.000208	0.00525	CbGeAlD
Methotrexate—MTHFR—head—epilepsy syndrome	0.000208	0.00524	CbGeAlD
Methotrexate—SLCO3A1—head—epilepsy syndrome	0.000205	0.00516	CbGeAlD
Methotrexate—PGD—spinal cord—epilepsy syndrome	0.000203	0.00512	CbGeAlD
Methotrexate—ATIC—brain—epilepsy syndrome	0.000203	0.00511	CbGeAlD
Methotrexate—MTHFR—nervous system—epilepsy syndrome	0.000197	0.00497	CbGeAlD
Methotrexate—ABCC10—medulla oblongata—epilepsy syndrome	0.000196	0.00493	CbGeAlD
Methotrexate—SLC16A1—midbrain—epilepsy syndrome	0.000195	0.0049	CbGeAlD
Methotrexate—SLCO3A1—nervous system—epilepsy syndrome	0.000194	0.00489	CbGeAlD
Methotrexate—MTHFR—central nervous system—epilepsy syndrome	0.00019	0.00478	CbGeAlD
Methotrexate—TYMS—head—epilepsy syndrome	0.00019	0.00478	CbGeAlD
Methotrexate—SLC16A1—spinal cord—epilepsy syndrome	0.00019	0.00478	CbGeAlD
Methotrexate—DHFR—head—epilepsy syndrome	0.000188	0.00474	CbGeAlD
Methotrexate—SLCO3A1—central nervous system—epilepsy syndrome	0.000187	0.00471	CbGeAlD
Methotrexate—MTHFR—cerebellum—epilepsy syndrome	0.000186	0.00468	CbGeAlD
Methotrexate—SLCO3A1—cerebellum—epilepsy syndrome	0.000183	0.0046	CbGeAlD
Methotrexate—PGD—head—epilepsy syndrome	0.000181	0.00455	CbGeAlD
Methotrexate—TYMS—nervous system—epilepsy syndrome	0.00018	0.00453	CbGeAlD
Methotrexate—ABCC10—midbrain—epilepsy syndrome	0.000179	0.0045	CbGeAlD
Methotrexate—DHFR—nervous system—epilepsy syndrome	0.000178	0.00449	CbGeAlD
Methotrexate—ABCC1—telencephalon—epilepsy syndrome	0.000176	0.00443	CbGeAlD
Methotrexate—Tetrahydrofolic acid—ABCC2—epilepsy syndrome	0.000176	0.0683	CrCbGaD
Methotrexate—ABCC10—spinal cord—epilepsy syndrome	0.000174	0.00439	CbGeAlD
Methotrexate—TYMS—central nervous system—epilepsy syndrome	0.000173	0.00437	CbGeAlD
Methotrexate—DHFR—central nervous system—epilepsy syndrome	0.000172	0.00432	CbGeAlD
Methotrexate—PGD—nervous system—epilepsy syndrome	0.000171	0.00432	CbGeAlD
Methotrexate—TYMS—cerebellum—epilepsy syndrome	0.000169	0.00427	CbGeAlD
Methotrexate—SLC16A1—head—epilepsy syndrome	0.000169	0.00425	CbGeAlD
Methotrexate—SLCO1C1—brain—epilepsy syndrome	0.000169	0.00425	CbGeAlD
Methotrexate—SLCO1A2—medulla oblongata—epilepsy syndrome	0.000169	0.00425	CbGeAlD
Methotrexate—DHFR—cerebellum—epilepsy syndrome	0.000168	0.00422	CbGeAlD
Methotrexate—PGD—central nervous system—epilepsy syndrome	0.000165	0.00416	CbGeAlD
Methotrexate—PGD—cerebellum—epilepsy syndrome	0.000161	0.00406	CbGeAlD
Methotrexate—SLC16A1—nervous system—epilepsy syndrome	0.00016	0.00403	CbGeAlD
Methotrexate—SLC22A7—brain—epilepsy syndrome	0.00016	0.00403	CbGeAlD
Methotrexate—ABCC3—head—epilepsy syndrome	0.000156	0.00392	CbGeAlD
Methotrexate—Folic Acid—ABCG2—epilepsy syndrome	0.000155	0.0604	CrCbGaD
Methotrexate—SLC22A6—brain—epilepsy syndrome	0.000154	0.00389	CbGeAlD
Methotrexate—SLCO1A2—midbrain—epilepsy syndrome	0.000154	0.00388	CbGeAlD
Methotrexate—SLC16A1—central nervous system—epilepsy syndrome	0.000154	0.00388	CbGeAlD
Methotrexate—MTHFR—brain—epilepsy syndrome	0.000151	0.0038	CbGeAlD
Methotrexate—SLC16A1—cerebellum—epilepsy syndrome	0.000151	0.00379	CbGeAlD
Methotrexate—SLCO1A2—spinal cord—epilepsy syndrome	0.00015	0.00379	CbGeAlD
Methotrexate—SLCO3A1—brain—epilepsy syndrome	0.000148	0.00374	CbGeAlD
Methotrexate—ABCC3—nervous system—epilepsy syndrome	0.000148	0.00372	CbGeAlD
Methotrexate—ABCG2—telencephalon—epilepsy syndrome	0.000146	0.00367	CbGeAlD
Methotrexate—ABCC3—central nervous system—epilepsy syndrome	0.000142	0.00358	CbGeAlD
Methotrexate—AOX1—cerebellum—epilepsy syndrome	0.000142	0.00358	CbGeAlD
Methotrexate—ABCC10—cerebellum—epilepsy syndrome	0.000138	0.00348	CbGeAlD
Methotrexate—TYMS—brain—epilepsy syndrome	0.000138	0.00347	CbGeAlD
Methotrexate—DHFR—brain—epilepsy syndrome	0.000136	0.00343	CbGeAlD
Methotrexate—SLCO1A2—head—epilepsy syndrome	0.000134	0.00336	CbGeAlD
Methotrexate—PGD—brain—epilepsy syndrome	0.000131	0.0033	CbGeAlD
Methotrexate—ABCC4—head—epilepsy syndrome	0.000129	0.00324	CbGeAlD
Methotrexate—SLC22A8—head—epilepsy syndrome	0.000128	0.00321	CbGeAlD
Methotrexate—SLCO1A2—nervous system—epilepsy syndrome	0.000127	0.00319	CbGeAlD
Methotrexate—SLC16A1—brain—epilepsy syndrome	0.000122	0.00308	CbGeAlD
Methotrexate—SLCO1A2—central nervous system—epilepsy syndrome	0.000122	0.00307	CbGeAlD
Methotrexate—ABCC4—nervous system—epilepsy syndrome	0.000122	0.00307	CbGeAlD
Methotrexate—SLC22A8—nervous system—epilepsy syndrome	0.000121	0.00305	CbGeAlD
Methotrexate—TYMS—Bortezomib—Lacosamide—epilepsy syndrome	0.00012	0.079	CbGdCrCtD
Methotrexate—SLCO1A2—cerebellum—epilepsy syndrome	0.000119	0.003	CbGeAlD
Methotrexate—ABCC4—central nervous system—epilepsy syndrome	0.000117	0.00296	CbGeAlD
Methotrexate—SLC22A8—central nervous system—epilepsy syndrome	0.000116	0.00293	CbGeAlD
Methotrexate—AOX1—brain—epilepsy syndrome	0.000115	0.00291	CbGeAlD
Methotrexate—ABCG2—medulla oblongata—epilepsy syndrome	0.000115	0.00288	CbGeAlD
Methotrexate—ABCC3—brain—epilepsy syndrome	0.000113	0.00284	CbGeAlD
Methotrexate—ABCC10—brain—epilepsy syndrome	0.000112	0.00283	CbGeAlD
Methotrexate—TYMS—Nortriptyline—Oxcarbazepine—epilepsy syndrome	0.00011	0.0726	CbGdCrCtD
Methotrexate—ABCG2—midbrain—epilepsy syndrome	0.000105	0.00264	CbGeAlD
Methotrexate—ABCG2—spinal cord—epilepsy syndrome	0.000102	0.00257	CbGeAlD
Methotrexate—ABCC1—cerebellum—epilepsy syndrome	9.78e-05	0.00246	CbGeAlD
Methotrexate—SLCO1A2—brain—epilepsy syndrome	9.68e-05	0.00244	CbGeAlD
Methotrexate—ALB—brain—epilepsy syndrome	9.63e-05	0.00242	CbGeAlD
Methotrexate—ABCC4—brain—epilepsy syndrome	9.32e-05	0.00235	CbGeAlD
Methotrexate—SLC22A8—brain—epilepsy syndrome	9.24e-05	0.00233	CbGeAlD
Methotrexate—TYMS—Chlorprothixene—Midazolam—epilepsy syndrome	8.9e-05	0.0587	CbGdCrCtD
Methotrexate—TYMS—Niclosamide—Clonazepam—epilepsy syndrome	8.31e-05	0.0548	CbGdCrCtD
Methotrexate—ABCG2—cerebellum—epilepsy syndrome	8.1e-05	0.00204	CbGeAlD
Methotrexate—ABCC1—brain—epilepsy syndrome	7.95e-05	0.002	CbGeAlD
Methotrexate—TYMS—Chlorprothixene—Diazepam—epilepsy syndrome	7.93e-05	0.0523	CbGdCrCtD
Methotrexate—ABCB1—forebrain—epilepsy syndrome	7.82e-05	0.00197	CbGeAlD
Methotrexate—ABCB1—telencephalon—epilepsy syndrome	7.19e-05	0.00181	CbGeAlD
Methotrexate—TYMS—Chlorpromazine—Clobazam—epilepsy syndrome	7.12e-05	0.047	CbGdCrCtD
Methotrexate—ABCG2—brain—epilepsy syndrome	6.58e-05	0.00166	CbGeAlD
Methotrexate—ABCB1—medulla oblongata—epilepsy syndrome	5.65e-05	0.00142	CbGeAlD
Methotrexate—ABCB1—midbrain—epilepsy syndrome	5.16e-05	0.0013	CbGeAlD
Methotrexate—ABCB1—spinal cord—epilepsy syndrome	5.04e-05	0.00127	CbGeAlD
Methotrexate—ABCB1—head—epilepsy syndrome	4.48e-05	0.00113	CbGeAlD
Methotrexate—ABCB1—nervous system—epilepsy syndrome	4.24e-05	0.00107	CbGeAlD
Methotrexate—ABCB1—central nervous system—epilepsy syndrome	4.09e-05	0.00103	CbGeAlD
Methotrexate—ABCB1—cerebellum—epilepsy syndrome	3.99e-05	0.00101	CbGeAlD
Methotrexate—ABCB1—brain—epilepsy syndrome	3.24e-05	0.000817	CbGeAlD
Methotrexate—Diarrhoea—Zonisamide—epilepsy syndrome	2.26e-05	0.000164	CcSEcCtD
Methotrexate—Pharyngitis—Topiramate—epilepsy syndrome	2.26e-05	0.000164	CcSEcCtD
Methotrexate—Asthenia—Oxcarbazepine—epilepsy syndrome	2.25e-05	0.000164	CcSEcCtD
Methotrexate—Pruritus—Clonazepam—epilepsy syndrome	2.25e-05	0.000164	CcSEcCtD
Methotrexate—Vomiting—Vigabatrin—epilepsy syndrome	2.25e-05	0.000163	CcSEcCtD
Methotrexate—Skin disorder—Valproic Acid—epilepsy syndrome	2.25e-05	0.000163	CcSEcCtD
Methotrexate—Urinary tract disorder—Topiramate—epilepsy syndrome	2.24e-05	0.000163	CcSEcCtD
Methotrexate—Hyperhidrosis—Valproic Acid—epilepsy syndrome	2.24e-05	0.000163	CcSEcCtD
Methotrexate—Cough—Pregabalin—epilepsy syndrome	2.24e-05	0.000163	CcSEcCtD
Methotrexate—Pruritus—Phenytoin—epilepsy syndrome	2.23e-05	0.000162	CcSEcCtD
Methotrexate—Nausea—Levetiracetam—epilepsy syndrome	2.23e-05	0.000162	CcSEcCtD
Methotrexate—Rash—Vigabatrin—epilepsy syndrome	2.23e-05	0.000162	CcSEcCtD
Methotrexate—Dizziness—Felbamate—epilepsy syndrome	2.23e-05	0.000162	CcSEcCtD
Methotrexate—Dermatitis—Vigabatrin—epilepsy syndrome	2.23e-05	0.000162	CcSEcCtD
Methotrexate—Urethral disorder—Topiramate—epilepsy syndrome	2.23e-05	0.000162	CcSEcCtD
Methotrexate—Pruritus—Oxcarbazepine—epilepsy syndrome	2.22e-05	0.000162	CcSEcCtD
Methotrexate—Convulsion—Pregabalin—epilepsy syndrome	2.22e-05	0.000162	CcSEcCtD
Methotrexate—Hypersensitivity—Carbamazepine—epilepsy syndrome	2.22e-05	0.000161	CcSEcCtD
Methotrexate—Vision blurred—Gabapentin—epilepsy syndrome	2.22e-05	0.000161	CcSEcCtD
Methotrexate—Headache—Vigabatrin—epilepsy syndrome	2.22e-05	0.000161	CcSEcCtD
Methotrexate—Vomiting—Diazepam—epilepsy syndrome	2.21e-05	0.000161	CcSEcCtD
Methotrexate—Anorexia—Valproic Acid—epilepsy syndrome	2.21e-05	0.00016	CcSEcCtD
Methotrexate—Rash—Diazepam—epilepsy syndrome	2.2e-05	0.00016	CcSEcCtD
Methotrexate—Dermatitis—Diazepam—epilepsy syndrome	2.19e-05	0.000159	CcSEcCtD
Methotrexate—Visual impairment—Topiramate—epilepsy syndrome	2.19e-05	0.000159	CcSEcCtD
Methotrexate—Myalgia—Pregabalin—epilepsy syndrome	2.18e-05	0.000159	CcSEcCtD
Methotrexate—Arthralgia—Pregabalin—epilepsy syndrome	2.18e-05	0.000159	CcSEcCtD
Methotrexate—Chest pain—Pregabalin—epilepsy syndrome	2.18e-05	0.000159	CcSEcCtD
Methotrexate—Ill-defined disorder—Gabapentin—epilepsy syndrome	2.18e-05	0.000159	CcSEcCtD
Methotrexate—Dizziness—Zonisamide—epilepsy syndrome	2.18e-05	0.000159	CcSEcCtD
Methotrexate—Headache—Diazepam—epilepsy syndrome	2.18e-05	0.000159	CcSEcCtD
Methotrexate—Diarrhoea—Clonazepam—epilepsy syndrome	2.18e-05	0.000158	CcSEcCtD
Methotrexate—Anaemia—Gabapentin—epilepsy syndrome	2.17e-05	0.000158	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	2.17e-05	0.000158	CcSEcCtD
Methotrexate—Hypotension—Valproic Acid—epilepsy syndrome	2.16e-05	0.000157	CcSEcCtD
Methotrexate—Asthenia—Carbamazepine—epilepsy syndrome	2.16e-05	0.000157	CcSEcCtD
Methotrexate—Diarrhoea—Phenytoin—epilepsy syndrome	2.16e-05	0.000157	CcSEcCtD
Methotrexate—Discomfort—Pregabalin—epilepsy syndrome	2.16e-05	0.000157	CcSEcCtD
Methotrexate—Nausea—Fosphenytoin—epilepsy syndrome	2.16e-05	0.000157	CcSEcCtD
Methotrexate—Diarrhoea—Oxcarbazepine—epilepsy syndrome	2.15e-05	0.000156	CcSEcCtD
Methotrexate—Erythema multiforme—Topiramate—epilepsy syndrome	2.15e-05	0.000156	CcSEcCtD
Methotrexate—Hypersensitivity—Lamotrigine—epilepsy syndrome	2.15e-05	0.000156	CcSEcCtD
Methotrexate—Vomiting—Felbamate—epilepsy syndrome	2.14e-05	0.000156	CcSEcCtD
Methotrexate—Pruritus—Carbamazepine—epilepsy syndrome	2.13e-05	0.000155	CcSEcCtD
Methotrexate—Rash—Felbamate—epilepsy syndrome	2.13e-05	0.000154	CcSEcCtD
Methotrexate—Eye disorder—Topiramate—epilepsy syndrome	2.12e-05	0.000154	CcSEcCtD
Methotrexate—Dermatitis—Felbamate—epilepsy syndrome	2.12e-05	0.000154	CcSEcCtD
Methotrexate—Malaise—Gabapentin—epilepsy syndrome	2.12e-05	0.000154	CcSEcCtD
Methotrexate—Tinnitus—Topiramate—epilepsy syndrome	2.12e-05	0.000154	CcSEcCtD
Methotrexate—Vertigo—Gabapentin—epilepsy syndrome	2.11e-05	0.000154	CcSEcCtD
Methotrexate—Headache—Felbamate—epilepsy syndrome	2.11e-05	0.000154	CcSEcCtD
Methotrexate—Confusional state—Pregabalin—epilepsy syndrome	2.11e-05	0.000153	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	2.11e-05	0.000153	CcSEcCtD
Methotrexate—Cardiac disorder—Topiramate—epilepsy syndrome	2.11e-05	0.000153	CcSEcCtD
Methotrexate—Leukopenia—Gabapentin—epilepsy syndrome	2.11e-05	0.000153	CcSEcCtD
Methotrexate—Dizziness—Clonazepam—epilepsy syndrome	2.1e-05	0.000153	CcSEcCtD
Methotrexate—Nausea—Vigabatrin—epilepsy syndrome	2.1e-05	0.000153	CcSEcCtD
Methotrexate—Vomiting—Zonisamide—epilepsy syndrome	2.1e-05	0.000152	CcSEcCtD
Methotrexate—Insomnia—Valproic Acid—epilepsy syndrome	2.09e-05	0.000152	CcSEcCtD
Methotrexate—Anaphylactic shock—Pregabalin—epilepsy syndrome	2.09e-05	0.000152	CcSEcCtD
Methotrexate—Asthenia—Lamotrigine—epilepsy syndrome	2.09e-05	0.000152	CcSEcCtD
Methotrexate—Dizziness—Phenytoin—epilepsy syndrome	2.09e-05	0.000152	CcSEcCtD
Methotrexate—Rash—Zonisamide—epilepsy syndrome	2.08e-05	0.000151	CcSEcCtD
Methotrexate—Infection—Pregabalin—epilepsy syndrome	2.08e-05	0.000151	CcSEcCtD
Methotrexate—Paraesthesia—Valproic Acid—epilepsy syndrome	2.08e-05	0.000151	CcSEcCtD
Methotrexate—Dermatitis—Zonisamide—epilepsy syndrome	2.08e-05	0.000151	CcSEcCtD
Methotrexate—Dizziness—Oxcarbazepine—epilepsy syndrome	2.08e-05	0.000151	CcSEcCtD
Methotrexate—Nausea—Diazepam—epilepsy syndrome	2.07e-05	0.00015	CcSEcCtD
Methotrexate—Headache—Zonisamide—epilepsy syndrome	2.07e-05	0.00015	CcSEcCtD
Methotrexate—Dyspnoea—Valproic Acid—epilepsy syndrome	2.06e-05	0.00015	CcSEcCtD
Methotrexate—Diarrhoea—Carbamazepine—epilepsy syndrome	2.06e-05	0.00015	CcSEcCtD
Methotrexate—Angiopathy—Topiramate—epilepsy syndrome	2.06e-05	0.00015	CcSEcCtD
Methotrexate—Pruritus—Lamotrigine—epilepsy syndrome	2.06e-05	0.00015	CcSEcCtD
Methotrexate—Somnolence—Valproic Acid—epilepsy syndrome	2.06e-05	0.00015	CcSEcCtD
Methotrexate—Immune system disorder—Topiramate—epilepsy syndrome	2.05e-05	0.000149	CcSEcCtD
Methotrexate—Nervous system disorder—Pregabalin—epilepsy syndrome	2.05e-05	0.000149	CcSEcCtD
Methotrexate—Cough—Gabapentin—epilepsy syndrome	2.05e-05	0.000149	CcSEcCtD
Methotrexate—Thrombocytopenia—Pregabalin—epilepsy syndrome	2.05e-05	0.000149	CcSEcCtD
Methotrexate—Mediastinal disorder—Topiramate—epilepsy syndrome	2.05e-05	0.000149	CcSEcCtD
Methotrexate—Chills—Topiramate—epilepsy syndrome	2.04e-05	0.000148	CcSEcCtD
Methotrexate—Dyspepsia—Valproic Acid—epilepsy syndrome	2.04e-05	0.000148	CcSEcCtD
Methotrexate—Convulsion—Gabapentin—epilepsy syndrome	2.04e-05	0.000148	CcSEcCtD
Methotrexate—Skin disorder—Pregabalin—epilepsy syndrome	2.03e-05	0.000148	CcSEcCtD
Methotrexate—Hyperhidrosis—Pregabalin—epilepsy syndrome	2.02e-05	0.000147	CcSEcCtD
Methotrexate—Vomiting—Clonazepam—epilepsy syndrome	2.02e-05	0.000147	CcSEcCtD
Methotrexate—Decreased appetite—Valproic Acid—epilepsy syndrome	2.01e-05	0.000146	CcSEcCtD
Methotrexate—Alopecia—Topiramate—epilepsy syndrome	2.01e-05	0.000146	CcSEcCtD
Methotrexate—Vomiting—Phenytoin—epilepsy syndrome	2.01e-05	0.000146	CcSEcCtD
Methotrexate—Rash—Clonazepam—epilepsy syndrome	2.01e-05	0.000146	CcSEcCtD
Methotrexate—Dermatitis—Clonazepam—epilepsy syndrome	2e-05	0.000146	CcSEcCtD
Methotrexate—Chest pain—Gabapentin—epilepsy syndrome	2e-05	0.000146	CcSEcCtD
Methotrexate—Arthralgia—Gabapentin—epilepsy syndrome	2e-05	0.000146	CcSEcCtD
Methotrexate—Myalgia—Gabapentin—epilepsy syndrome	2e-05	0.000146	CcSEcCtD
Methotrexate—Nausea—Felbamate—epilepsy syndrome	2e-05	0.000146	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	2e-05	0.000145	CcSEcCtD
Methotrexate—Vomiting—Oxcarbazepine—epilepsy syndrome	2e-05	0.000145	CcSEcCtD
Methotrexate—Fatigue—Valproic Acid—epilepsy syndrome	2e-05	0.000145	CcSEcCtD
Methotrexate—Anorexia—Pregabalin—epilepsy syndrome	2e-05	0.000145	CcSEcCtD
Methotrexate—Dizziness—Carbamazepine—epilepsy syndrome	1.99e-05	0.000145	CcSEcCtD
Methotrexate—Diarrhoea—Lamotrigine—epilepsy syndrome	1.99e-05	0.000145	CcSEcCtD
Methotrexate—Headache—Clonazepam—epilepsy syndrome	1.99e-05	0.000145	CcSEcCtD
Methotrexate—Rash—Phenytoin—epilepsy syndrome	1.99e-05	0.000145	CcSEcCtD
Methotrexate—Mental disorder—Topiramate—epilepsy syndrome	1.99e-05	0.000145	CcSEcCtD
Methotrexate—Dermatitis—Phenytoin—epilepsy syndrome	1.99e-05	0.000145	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	1.99e-05	0.000145	CcSEcCtD
Methotrexate—Rash—Oxcarbazepine—epilepsy syndrome	1.98e-05	0.000144	CcSEcCtD
Methotrexate—Pain—Valproic Acid—epilepsy syndrome	1.98e-05	0.000144	CcSEcCtD
Methotrexate—Dermatitis—Oxcarbazepine—epilepsy syndrome	1.98e-05	0.000144	CcSEcCtD
Methotrexate—Headache—Phenytoin—epilepsy syndrome	1.98e-05	0.000144	CcSEcCtD
Methotrexate—Erythema—Topiramate—epilepsy syndrome	1.98e-05	0.000144	CcSEcCtD
Methotrexate—Malnutrition—Topiramate—epilepsy syndrome	1.98e-05	0.000144	CcSEcCtD
Methotrexate—Discomfort—Gabapentin—epilepsy syndrome	1.98e-05	0.000144	CcSEcCtD
Methotrexate—Headache—Oxcarbazepine—epilepsy syndrome	1.97e-05	0.000143	CcSEcCtD
Methotrexate—Nausea—Zonisamide—epilepsy syndrome	1.96e-05	0.000142	CcSEcCtD
Methotrexate—Hypotension—Pregabalin—epilepsy syndrome	1.96e-05	0.000142	CcSEcCtD
Methotrexate—Dysgeusia—Topiramate—epilepsy syndrome	1.94e-05	0.000141	CcSEcCtD
Methotrexate—Confusional state—Gabapentin—epilepsy syndrome	1.94e-05	0.000141	CcSEcCtD
Methotrexate—Dizziness—Lamotrigine—epilepsy syndrome	1.93e-05	0.00014	CcSEcCtD
Methotrexate—Anaphylactic shock—Gabapentin—epilepsy syndrome	1.92e-05	0.00014	CcSEcCtD
Methotrexate—Vomiting—Carbamazepine—epilepsy syndrome	1.92e-05	0.000139	CcSEcCtD
Methotrexate—Back pain—Topiramate—epilepsy syndrome	1.91e-05	0.000139	CcSEcCtD
Methotrexate—Feeling abnormal—Valproic Acid—epilepsy syndrome	1.91e-05	0.000139	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	1.91e-05	0.000139	CcSEcCtD
Methotrexate—Infection—Gabapentin—epilepsy syndrome	1.91e-05	0.000139	CcSEcCtD
Methotrexate—Rash—Carbamazepine—epilepsy syndrome	1.9e-05	0.000138	CcSEcCtD
Methotrexate—Dermatitis—Carbamazepine—epilepsy syndrome	1.9e-05	0.000138	CcSEcCtD
Methotrexate—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	1.89e-05	0.000138	CcSEcCtD
Methotrexate—Insomnia—Pregabalin—epilepsy syndrome	1.89e-05	0.000138	CcSEcCtD
Methotrexate—Nausea—Clonazepam—epilepsy syndrome	1.89e-05	0.000137	CcSEcCtD
Methotrexate—Headache—Carbamazepine—epilepsy syndrome	1.89e-05	0.000137	CcSEcCtD
Methotrexate—Nervous system disorder—Gabapentin—epilepsy syndrome	1.88e-05	0.000137	CcSEcCtD
Methotrexate—Paraesthesia—Pregabalin—epilepsy syndrome	1.88e-05	0.000137	CcSEcCtD
Methotrexate—Thrombocytopenia—Gabapentin—epilepsy syndrome	1.88e-05	0.000137	CcSEcCtD
Methotrexate—Nausea—Phenytoin—epilepsy syndrome	1.88e-05	0.000136	CcSEcCtD
Methotrexate—Dyspnoea—Pregabalin—epilepsy syndrome	1.87e-05	0.000136	CcSEcCtD
Methotrexate—Nausea—Oxcarbazepine—epilepsy syndrome	1.87e-05	0.000136	CcSEcCtD
Methotrexate—Vision blurred—Topiramate—epilepsy syndrome	1.86e-05	0.000136	CcSEcCtD
Methotrexate—Skin disorder—Gabapentin—epilepsy syndrome	1.86e-05	0.000136	CcSEcCtD
Methotrexate—Somnolence—Pregabalin—epilepsy syndrome	1.86e-05	0.000135	CcSEcCtD
Methotrexate—Hyperhidrosis—Gabapentin—epilepsy syndrome	1.86e-05	0.000135	CcSEcCtD
Methotrexate—Vomiting—Lamotrigine—epilepsy syndrome	1.85e-05	0.000135	CcSEcCtD
Methotrexate—Urticaria—Valproic Acid—epilepsy syndrome	1.84e-05	0.000134	CcSEcCtD
Methotrexate—Rash—Lamotrigine—epilepsy syndrome	1.84e-05	0.000134	CcSEcCtD
Methotrexate—Ill-defined disorder—Topiramate—epilepsy syndrome	1.84e-05	0.000133	CcSEcCtD
Methotrexate—Dermatitis—Lamotrigine—epilepsy syndrome	1.84e-05	0.000133	CcSEcCtD
Methotrexate—Abdominal pain—Valproic Acid—epilepsy syndrome	1.83e-05	0.000133	CcSEcCtD
Methotrexate—Body temperature increased—Valproic Acid—epilepsy syndrome	1.83e-05	0.000133	CcSEcCtD
Methotrexate—Anorexia—Gabapentin—epilepsy syndrome	1.83e-05	0.000133	CcSEcCtD
Methotrexate—Anaemia—Topiramate—epilepsy syndrome	1.83e-05	0.000133	CcSEcCtD
Methotrexate—Headache—Lamotrigine—epilepsy syndrome	1.83e-05	0.000133	CcSEcCtD
Methotrexate—Decreased appetite—Pregabalin—epilepsy syndrome	1.82e-05	0.000132	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	1.81e-05	0.000131	CcSEcCtD
Methotrexate—Fatigue—Pregabalin—epilepsy syndrome	1.8e-05	0.000131	CcSEcCtD
Methotrexate—Hypotension—Gabapentin—epilepsy syndrome	1.79e-05	0.00013	CcSEcCtD
Methotrexate—Nausea—Carbamazepine—epilepsy syndrome	1.79e-05	0.00013	CcSEcCtD
Methotrexate—Pain—Pregabalin—epilepsy syndrome	1.79e-05	0.00013	CcSEcCtD
Methotrexate—Malaise—Topiramate—epilepsy syndrome	1.78e-05	0.00013	CcSEcCtD
Methotrexate—Vertigo—Topiramate—epilepsy syndrome	1.78e-05	0.000129	CcSEcCtD
Methotrexate—Leukopenia—Topiramate—epilepsy syndrome	1.77e-05	0.000129	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	1.75e-05	0.000127	CcSEcCtD
Methotrexate—Insomnia—Gabapentin—epilepsy syndrome	1.74e-05	0.000126	CcSEcCtD
Methotrexate—Nausea—Lamotrigine—epilepsy syndrome	1.73e-05	0.000126	CcSEcCtD
Methotrexate—Cough—Topiramate—epilepsy syndrome	1.73e-05	0.000126	CcSEcCtD
Methotrexate—Feeling abnormal—Pregabalin—epilepsy syndrome	1.73e-05	0.000125	CcSEcCtD
Methotrexate—Paraesthesia—Gabapentin—epilepsy syndrome	1.72e-05	0.000125	CcSEcCtD
Methotrexate—Convulsion—Topiramate—epilepsy syndrome	1.71e-05	0.000125	CcSEcCtD
Methotrexate—Gastrointestinal pain—Pregabalin—epilepsy syndrome	1.71e-05	0.000124	CcSEcCtD
Methotrexate—Dyspnoea—Gabapentin—epilepsy syndrome	1.71e-05	0.000124	CcSEcCtD
Methotrexate—Somnolence—Gabapentin—epilepsy syndrome	1.71e-05	0.000124	CcSEcCtD
Methotrexate—Hypersensitivity—Valproic Acid—epilepsy syndrome	1.71e-05	0.000124	CcSEcCtD
Methotrexate—Dyspepsia—Gabapentin—epilepsy syndrome	1.69e-05	0.000123	CcSEcCtD
Methotrexate—Chest pain—Topiramate—epilepsy syndrome	1.68e-05	0.000122	CcSEcCtD
Methotrexate—Arthralgia—Topiramate—epilepsy syndrome	1.68e-05	0.000122	CcSEcCtD
Methotrexate—Myalgia—Topiramate—epilepsy syndrome	1.68e-05	0.000122	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	1.67e-05	0.000122	CcSEcCtD
Methotrexate—Decreased appetite—Gabapentin—epilepsy syndrome	1.67e-05	0.000121	CcSEcCtD
Methotrexate—Discomfort—Topiramate—epilepsy syndrome	1.66e-05	0.000121	CcSEcCtD
Methotrexate—Urticaria—Pregabalin—epilepsy syndrome	1.66e-05	0.000121	CcSEcCtD
Methotrexate—Asthenia—Valproic Acid—epilepsy syndrome	1.66e-05	0.000121	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	1.66e-05	0.00012	CcSEcCtD
Methotrexate—Fatigue—Gabapentin—epilepsy syndrome	1.65e-05	0.00012	CcSEcCtD
Methotrexate—Abdominal pain—Pregabalin—epilepsy syndrome	1.65e-05	0.00012	CcSEcCtD
Methotrexate—Body temperature increased—Pregabalin—epilepsy syndrome	1.65e-05	0.00012	CcSEcCtD
Methotrexate—Pain—Gabapentin—epilepsy syndrome	1.64e-05	0.000119	CcSEcCtD
Methotrexate—Pruritus—Valproic Acid—epilepsy syndrome	1.64e-05	0.000119	CcSEcCtD
Methotrexate—Confusional state—Topiramate—epilepsy syndrome	1.63e-05	0.000118	CcSEcCtD
Methotrexate—Infection—Topiramate—epilepsy syndrome	1.6e-05	0.000117	CcSEcCtD
Methotrexate—Diarrhoea—Valproic Acid—epilepsy syndrome	1.58e-05	0.000115	CcSEcCtD
Methotrexate—Nervous system disorder—Topiramate—epilepsy syndrome	1.58e-05	0.000115	CcSEcCtD
Methotrexate—Feeling abnormal—Gabapentin—epilepsy syndrome	1.58e-05	0.000115	CcSEcCtD
Methotrexate—Thrombocytopenia—Topiramate—epilepsy syndrome	1.58e-05	0.000115	CcSEcCtD
Methotrexate—Gastrointestinal pain—Gabapentin—epilepsy syndrome	1.57e-05	0.000114	CcSEcCtD
Methotrexate—Skin disorder—Topiramate—epilepsy syndrome	1.57e-05	0.000114	CcSEcCtD
Methotrexate—Hyperhidrosis—Topiramate—epilepsy syndrome	1.56e-05	0.000113	CcSEcCtD
Methotrexate—Hypersensitivity—Pregabalin—epilepsy syndrome	1.54e-05	0.000112	CcSEcCtD
Methotrexate—Anorexia—Topiramate—epilepsy syndrome	1.54e-05	0.000112	CcSEcCtD
Methotrexate—Dizziness—Valproic Acid—epilepsy syndrome	1.53e-05	0.000111	CcSEcCtD
Methotrexate—Urticaria—Gabapentin—epilepsy syndrome	1.52e-05	0.000111	CcSEcCtD
Methotrexate—Body temperature increased—Gabapentin—epilepsy syndrome	1.52e-05	0.00011	CcSEcCtD
Methotrexate—Abdominal pain—Gabapentin—epilepsy syndrome	1.52e-05	0.00011	CcSEcCtD
Methotrexate—Hypotension—Topiramate—epilepsy syndrome	1.51e-05	0.00011	CcSEcCtD
Methotrexate—Asthenia—Pregabalin—epilepsy syndrome	1.5e-05	0.000109	CcSEcCtD
Methotrexate—Pruritus—Pregabalin—epilepsy syndrome	1.48e-05	0.000108	CcSEcCtD
Methotrexate—Vomiting—Valproic Acid—epilepsy syndrome	1.47e-05	0.000107	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	1.47e-05	0.000107	CcSEcCtD
Methotrexate—Insomnia—Topiramate—epilepsy syndrome	1.46e-05	0.000106	CcSEcCtD
Methotrexate—Rash—Valproic Acid—epilepsy syndrome	1.46e-05	0.000106	CcSEcCtD
Methotrexate—Dermatitis—Valproic Acid—epilepsy syndrome	1.46e-05	0.000106	CcSEcCtD
Methotrexate—Headache—Valproic Acid—epilepsy syndrome	1.45e-05	0.000105	CcSEcCtD
Methotrexate—Paraesthesia—Topiramate—epilepsy syndrome	1.45e-05	0.000105	CcSEcCtD
Methotrexate—Dyspnoea—Topiramate—epilepsy syndrome	1.44e-05	0.000105	CcSEcCtD
Methotrexate—Somnolence—Topiramate—epilepsy syndrome	1.44e-05	0.000104	CcSEcCtD
Methotrexate—Diarrhoea—Pregabalin—epilepsy syndrome	1.43e-05	0.000104	CcSEcCtD
Methotrexate—Dyspepsia—Topiramate—epilepsy syndrome	1.42e-05	0.000103	CcSEcCtD
Methotrexate—Hypersensitivity—Gabapentin—epilepsy syndrome	1.41e-05	0.000103	CcSEcCtD
Methotrexate—Decreased appetite—Topiramate—epilepsy syndrome	1.4e-05	0.000102	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Topiramate—epilepsy syndrome	1.39e-05	0.000101	CcSEcCtD
Methotrexate—Fatigue—Topiramate—epilepsy syndrome	1.39e-05	0.000101	CcSEcCtD
Methotrexate—Dizziness—Pregabalin—epilepsy syndrome	1.38e-05	0.000101	CcSEcCtD
Methotrexate—Pain—Topiramate—epilepsy syndrome	1.38e-05	0.0001	CcSEcCtD
Methotrexate—Asthenia—Gabapentin—epilepsy syndrome	1.38e-05	0.0001	CcSEcCtD
Methotrexate—Nausea—Valproic Acid—epilepsy syndrome	1.38e-05	0.0001	CcSEcCtD
Methotrexate—Pruritus—Gabapentin—epilepsy syndrome	1.36e-05	9.87e-05	CcSEcCtD
Methotrexate—Vomiting—Pregabalin—epilepsy syndrome	1.33e-05	9.68e-05	CcSEcCtD
Methotrexate—Feeling abnormal—Topiramate—epilepsy syndrome	1.33e-05	9.67e-05	CcSEcCtD
Methotrexate—Gastrointestinal pain—Topiramate—epilepsy syndrome	1.32e-05	9.6e-05	CcSEcCtD
Methotrexate—Rash—Pregabalin—epilepsy syndrome	1.32e-05	9.59e-05	CcSEcCtD
Methotrexate—Dermatitis—Pregabalin—epilepsy syndrome	1.32e-05	9.59e-05	CcSEcCtD
Methotrexate—Diarrhoea—Gabapentin—epilepsy syndrome	1.31e-05	9.55e-05	CcSEcCtD
Methotrexate—Headache—Pregabalin—epilepsy syndrome	1.31e-05	9.53e-05	CcSEcCtD
Methotrexate—Urticaria—Topiramate—epilepsy syndrome	1.28e-05	9.33e-05	CcSEcCtD
Methotrexate—Abdominal pain—Topiramate—epilepsy syndrome	1.28e-05	9.28e-05	CcSEcCtD
Methotrexate—Body temperature increased—Topiramate—epilepsy syndrome	1.28e-05	9.28e-05	CcSEcCtD
Methotrexate—Dizziness—Gabapentin—epilepsy syndrome	1.27e-05	9.23e-05	CcSEcCtD
Methotrexate—Nausea—Pregabalin—epilepsy syndrome	1.24e-05	9.04e-05	CcSEcCtD
Methotrexate—Vomiting—Gabapentin—epilepsy syndrome	1.22e-05	8.87e-05	CcSEcCtD
Methotrexate—Rash—Gabapentin—epilepsy syndrome	1.21e-05	8.8e-05	CcSEcCtD
Methotrexate—Dermatitis—Gabapentin—epilepsy syndrome	1.21e-05	8.79e-05	CcSEcCtD
Methotrexate—Headache—Gabapentin—epilepsy syndrome	1.2e-05	8.74e-05	CcSEcCtD
Methotrexate—Hypersensitivity—Topiramate—epilepsy syndrome	1.19e-05	8.65e-05	CcSEcCtD
Methotrexate—Asthenia—Topiramate—epilepsy syndrome	1.16e-05	8.42e-05	CcSEcCtD
Methotrexate—Pruritus—Topiramate—epilepsy syndrome	1.14e-05	8.31e-05	CcSEcCtD
Methotrexate—Nausea—Gabapentin—epilepsy syndrome	1.14e-05	8.29e-05	CcSEcCtD
Methotrexate—Diarrhoea—Topiramate—epilepsy syndrome	1.1e-05	8.03e-05	CcSEcCtD
Methotrexate—Dizziness—Topiramate—epilepsy syndrome	1.07e-05	7.76e-05	CcSEcCtD
Methotrexate—Vomiting—Topiramate—epilepsy syndrome	1.03e-05	7.46e-05	CcSEcCtD
Methotrexate—Rash—Topiramate—epilepsy syndrome	1.02e-05	7.4e-05	CcSEcCtD
Methotrexate—Dermatitis—Topiramate—epilepsy syndrome	1.02e-05	7.39e-05	CcSEcCtD
Methotrexate—Headache—Topiramate—epilepsy syndrome	1.01e-05	7.35e-05	CcSEcCtD
Methotrexate—Nausea—Topiramate—epilepsy syndrome	9.59e-06	6.97e-05	CcSEcCtD
Methotrexate—SLCO1B3—Metabolism—ABCB1—epilepsy syndrome	2.34e-06	2.67e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—APOE—epilepsy syndrome	2.34e-06	2.66e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CACNA1A—epilepsy syndrome	2.33e-06	2.65e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ALDH7A1—epilepsy syndrome	2.33e-06	2.65e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—SLC2A1—epilepsy syndrome	2.33e-06	2.65e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—FGF2—epilepsy syndrome	2.33e-06	2.65e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	2.32e-06	2.65e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CYP2D6—epilepsy syndrome	2.32e-06	2.64e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—epilepsy syndrome	2.32e-06	2.64e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT3—epilepsy syndrome	2.31e-06	2.63e-05	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—ALB—epilepsy syndrome	2.31e-06	2.63e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PLCB1—epilepsy syndrome	2.3e-06	2.62e-05	CbGpPWpGaD
Methotrexate—FPGS—Disease—AKT1—epilepsy syndrome	2.3e-06	2.62e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—TH—epilepsy syndrome	2.3e-06	2.62e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ST3GAL3—epilepsy syndrome	2.28e-06	2.6e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP2C19—epilepsy syndrome	2.27e-06	2.59e-05	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—AKT1—epilepsy syndrome	2.26e-06	2.58e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	2.26e-06	2.57e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP11A1—epilepsy syndrome	2.26e-06	2.57e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—POMC—epilepsy syndrome	2.26e-06	2.57e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ASAH1—epilepsy syndrome	2.26e-06	2.57e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ADAM10—epilepsy syndrome	2.26e-06	2.57e-05	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—ALB—epilepsy syndrome	2.24e-06	2.55e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ADSL—epilepsy syndrome	2.23e-06	2.55e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—PLAT—epilepsy syndrome	2.23e-06	2.54e-05	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	2.21e-06	2.52e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	2.21e-06	2.52e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ADRA2A—epilepsy syndrome	2.21e-06	2.51e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—POMC—epilepsy syndrome	2.21e-06	2.51e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CYP2D6—epilepsy syndrome	2.2e-06	2.51e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—HMOX1—epilepsy syndrome	2.2e-06	2.51e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—BCHE—epilepsy syndrome	2.2e-06	2.5e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—STXBP1—epilepsy syndrome	2.2e-06	2.5e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GLUL—epilepsy syndrome	2.19e-06	2.5e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—GPX1—epilepsy syndrome	2.18e-06	2.48e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—AGT—epilepsy syndrome	2.17e-06	2.47e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CAT—epilepsy syndrome	2.17e-06	2.47e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MTOR—epilepsy syndrome	2.17e-06	2.47e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—SRC—epilepsy syndrome	2.17e-06	2.47e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—epilepsy syndrome	2.15e-06	2.45e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CACNA1D—epilepsy syndrome	2.15e-06	2.45e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PTGS2—epilepsy syndrome	2.15e-06	2.45e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NT5E—epilepsy syndrome	2.14e-06	2.44e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALAD—epilepsy syndrome	2.14e-06	2.44e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—SLC2A1—epilepsy syndrome	2.13e-06	2.43e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—APOE—epilepsy syndrome	2.13e-06	2.42e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—MTOR—epilepsy syndrome	2.12e-06	2.41e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—FGF2—epilepsy syndrome	2.12e-06	2.41e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ABCB1—epilepsy syndrome	2.11e-06	2.41e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—VEGFA—epilepsy syndrome	2.11e-06	2.41e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDC42—epilepsy syndrome	2.11e-06	2.4e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—FYN—epilepsy syndrome	2.1e-06	2.4e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	2.1e-06	2.39e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—PTGS2—epilepsy syndrome	2.1e-06	2.39e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ADRA2A—epilepsy syndrome	2.1e-06	2.39e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—SLC2A1—epilepsy syndrome	2.1e-06	2.39e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—epilepsy syndrome	2.09e-06	2.38e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—BCHE—epilepsy syndrome	2.09e-06	2.38e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—AGT—epilepsy syndrome	2.08e-06	2.37e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PLCB1—epilepsy syndrome	2.07e-06	2.36e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—TH—epilepsy syndrome	2.07e-06	2.35e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—ALB—epilepsy syndrome	2.06e-06	2.34e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CACNA1A—epilepsy syndrome	2.04e-06	2.33e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALDH7A1—epilepsy syndrome	2.04e-06	2.33e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP2D6—epilepsy syndrome	2.04e-06	2.32e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—APOE—epilepsy syndrome	2.04e-06	2.32e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	2.03e-06	2.32e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—YWHAZ—epilepsy syndrome	2.02e-06	2.3e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TXNRD1—epilepsy syndrome	2.01e-06	2.29e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—ALB—epilepsy syndrome	2.01e-06	2.29e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—POMC—epilepsy syndrome	2.01e-06	2.29e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—HMOX1—epilepsy syndrome	2e-06	2.28e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ST3GAL3—epilepsy syndrome	2e-06	2.28e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—SLC2A1—epilepsy syndrome	1.99e-06	2.27e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—AVP—epilepsy syndrome	1.98e-06	2.26e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PLCB1—epilepsy syndrome	1.97e-06	2.24e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—GPX1—epilepsy syndrome	1.96e-06	2.24e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—TH—epilepsy syndrome	1.96e-06	2.24e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ADSL—epilepsy syndrome	1.96e-06	2.23e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AQP1—epilepsy syndrome	1.95e-06	2.22e-05	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—ALB—epilepsy syndrome	1.95e-06	2.22e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ADRA2A—epilepsy syndrome	1.94e-06	2.21e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—BCHE—epilepsy syndrome	1.93e-06	2.2e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.93e-06	2.2e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HES1—epilepsy syndrome	1.93e-06	2.2e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MTOR—epilepsy syndrome	1.93e-06	2.2e-05	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—AKT1—epilepsy syndrome	1.93e-06	2.19e-05	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—AKT1—epilepsy syndrome	1.93e-06	2.19e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GLUL—epilepsy syndrome	1.92e-06	2.19e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—ABCB1—epilepsy syndrome	1.92e-06	2.19e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—HMOX1—epilepsy syndrome	1.92e-06	2.18e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTGS2—epilepsy syndrome	1.91e-06	2.18e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AGT—epilepsy syndrome	1.91e-06	2.17e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—SRC—epilepsy syndrome	1.9e-06	2.17e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CAT—epilepsy syndrome	1.89e-06	2.15e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CACNA1D—epilepsy syndrome	1.88e-06	2.15e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—FYN—epilepsy syndrome	1.88e-06	2.14e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	1.88e-06	2.14e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—epilepsy syndrome	1.87e-06	2.13e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—APOE—epilepsy syndrome	1.87e-06	2.13e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—H2AFX—epilepsy syndrome	1.87e-06	2.13e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—VEGFA—epilepsy syndrome	1.85e-06	2.11e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—SLC2A1—epilepsy syndrome	1.84e-06	2.1e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ABCB1—epilepsy syndrome	1.84e-06	2.09e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—ALB—epilepsy syndrome	1.83e-06	2.08e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—POMC—epilepsy syndrome	1.83e-06	2.08e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—epilepsy syndrome	1.83e-06	2.08e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PLCB1—epilepsy syndrome	1.82e-06	2.08e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—TH—epilepsy syndrome	1.82e-06	2.07e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—AKT1—epilepsy syndrome	1.81e-06	2.06e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—YWHAZ—epilepsy syndrome	1.8e-06	2.05e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTGS2—epilepsy syndrome	1.8e-06	2.05e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PLAU—epilepsy syndrome	1.8e-06	2.05e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—AKT1—epilepsy syndrome	1.79e-06	2.04e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—KCNJ11—epilepsy syndrome	1.77e-06	2.01e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CHRM3—epilepsy syndrome	1.77e-06	2.01e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TXNRD1—epilepsy syndrome	1.76e-06	2.01e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTGS2—epilepsy syndrome	1.76e-06	2e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—HMOX1—epilepsy syndrome	1.75e-06	1.99e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—POMC—epilepsy syndrome	1.75e-06	1.99e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—SRC—epilepsy syndrome	1.74e-06	1.98e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—AVP—epilepsy syndrome	1.74e-06	1.98e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CCR5—epilepsy syndrome	1.73e-06	1.98e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—HMOX1—epilepsy syndrome	1.72e-06	1.96e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AGT—epilepsy syndrome	1.72e-06	1.96e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AQP1—epilepsy syndrome	1.71e-06	1.95e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GPX1—epilepsy syndrome	1.71e-06	1.95e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CAT—epilepsy syndrome	1.7e-06	1.94e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—SRC—epilepsy syndrome	1.7e-06	1.94e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—APOE—epilepsy syndrome	1.69e-06	1.92e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PRKCB—epilepsy syndrome	1.67e-06	1.9e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—ALB—epilepsy syndrome	1.67e-06	1.9e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ABCB1—epilepsy syndrome	1.65e-06	1.89e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—NOS2—epilepsy syndrome	1.65e-06	1.88e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	1.64e-06	1.87e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—HMOX1—epilepsy syndrome	1.64e-06	1.87e-05	CbGpPWpGaD
Methotrexate—PGD—Disease—AKT1—epilepsy syndrome	1.64e-06	1.87e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CAT—epilepsy syndrome	1.62e-06	1.84e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TSC2—epilepsy syndrome	1.61e-06	1.84e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	1.61e-06	1.84e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—POMC—epilepsy syndrome	1.61e-06	1.83e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTGS2—epilepsy syndrome	1.6e-06	1.82e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—ALB—epilepsy syndrome	1.6e-06	1.82e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—APOE—epilepsy syndrome	1.58e-06	1.8e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ABCB1—epilepsy syndrome	1.57e-06	1.79e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—epilepsy syndrome	1.56e-06	1.78e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—KCNJ11—epilepsy syndrome	1.55e-06	1.76e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CHRM3—epilepsy syndrome	1.55e-06	1.76e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—SRC—epilepsy syndrome	1.55e-06	1.76e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GPX1—epilepsy syndrome	1.54e-06	1.75e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—HMOX1—epilepsy syndrome	1.52e-06	1.73e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—AKT1—epilepsy syndrome	1.5e-06	1.71e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AGT—epilepsy syndrome	1.5e-06	1.71e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CAT—epilepsy syndrome	1.5e-06	1.71e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IL6ST—epilepsy syndrome	1.48e-06	1.69e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NOS2—epilepsy syndrome	1.47e-06	1.68e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—APOE—epilepsy syndrome	1.47e-06	1.67e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ALB—epilepsy syndrome	1.46e-06	1.67e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GPX1—epilepsy syndrome	1.46e-06	1.67e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTGS2—epilepsy syndrome	1.46e-06	1.66e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ABCB1—epilepsy syndrome	1.46e-06	1.66e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—POMC—epilepsy syndrome	1.45e-06	1.65e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ABCG2—epilepsy syndrome	1.44e-06	1.64e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP2C19—epilepsy syndrome	1.4e-06	1.6e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTGS2—epilepsy syndrome	1.4e-06	1.59e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP11A1—epilepsy syndrome	1.39e-06	1.59e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	1.38e-06	1.58e-05	CbGpPWpGaD
Methotrexate—PGD—Metabolism—AKT1—epilepsy syndrome	1.37e-06	1.56e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GPX1—epilepsy syndrome	1.35e-06	1.54e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AGT—epilepsy syndrome	1.35e-06	1.54e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—AKT1—epilepsy syndrome	1.35e-06	1.53e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—APOE—epilepsy syndrome	1.32e-06	1.51e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ALB—epilepsy syndrome	1.32e-06	1.5e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AGT—epilepsy syndrome	1.28e-06	1.46e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTGS2—epilepsy syndrome	1.28e-06	1.46e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—POMC—epilepsy syndrome	1.26e-06	1.44e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ABCG2—epilepsy syndrome	1.26e-06	1.44e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP2D6—epilepsy syndrome	1.26e-06	1.43e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—APOE—epilepsy syndrome	1.26e-06	1.43e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP2C19—epilepsy syndrome	1.23e-06	1.4e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP11A1—epilepsy syndrome	1.22e-06	1.39e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—FGF2—epilepsy syndrome	1.2e-06	1.37e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ADRA2A—epilepsy syndrome	1.2e-06	1.36e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—BCHE—epilepsy syndrome	1.19e-06	1.36e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AGT—epilepsy syndrome	1.19e-06	1.35e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—AKT1—epilepsy syndrome	1.18e-06	1.35e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	1.16e-06	1.33e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—APOE—epilepsy syndrome	1.16e-06	1.32e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTGS2—epilepsy syndrome	1.16e-06	1.32e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ALB—epilepsy syndrome	1.15e-06	1.31e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SLC2A1—epilepsy syndrome	1.14e-06	1.3e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—POMC—epilepsy syndrome	1.14e-06	1.29e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PLCB1—epilepsy syndrome	1.13e-06	1.28e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TH—epilepsy syndrome	1.12e-06	1.28e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.1e-06	1.26e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP2D6—epilepsy syndrome	1.1e-06	1.26e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MTOR—epilepsy syndrome	1.09e-06	1.24e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTGS2—epilepsy syndrome	1.08e-06	1.23e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—AKT1—epilepsy syndrome	1.08e-06	1.23e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—POMC—epilepsy syndrome	1.08e-06	1.23e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—AKT1—epilepsy syndrome	1.06e-06	1.2e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	1.05e-06	1.2e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ADRA2A—epilepsy syndrome	1.05e-06	1.2e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—BCHE—epilepsy syndrome	1.05e-06	1.19e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ALB—epilepsy syndrome	1.04e-06	1.18e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTGS2—epilepsy syndrome	1.01e-06	1.15e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—POMC—epilepsy syndrome	9.99e-07	1.14e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC2A1—epilepsy syndrome	9.97e-07	1.14e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PLCB1—epilepsy syndrome	9.86e-07	1.12e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ALB—epilepsy syndrome	9.84e-07	1.12e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TH—epilepsy syndrome	9.83e-07	1.12e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—SRC—epilepsy syndrome	9.81e-07	1.12e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—AKT1—epilepsy syndrome	9.6e-07	1.09e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—epilepsy syndrome	9.55e-07	1.09e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HMOX1—epilepsy syndrome	9.36e-07	1.07e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CAT—epilepsy syndrome	9.24e-07	1.05e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ALB—epilepsy syndrome	9.11e-07	1.04e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTGS2—epilepsy syndrome	9.06e-07	1.03e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—AKT1—epilepsy syndrome	9.05e-07	1.03e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ABCB1—epilepsy syndrome	8.99e-07	1.02e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—AKT1—epilepsy syndrome	8.84e-07	1.01e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SRC—epilepsy syndrome	8.75e-07	9.96e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTGS2—epilepsy syndrome	8.61e-07	9.8e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GPX1—epilepsy syndrome	8.35e-07	9.52e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HMOX1—epilepsy syndrome	8.2e-07	9.34e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CAT—epilepsy syndrome	8.09e-07	9.22e-06	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—AKT1—epilepsy syndrome	8.04e-07	9.16e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTGS2—epilepsy syndrome	7.97e-07	9.08e-06	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—AKT1—epilepsy syndrome	7.33e-07	8.34e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AGT—epilepsy syndrome	7.33e-07	8.34e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GPX1—epilepsy syndrome	7.32e-07	8.34e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—APOE—epilepsy syndrome	7.18e-07	8.18e-06	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—AKT1—epilepsy syndrome	7.02e-07	7.99e-06	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AKT1—epilepsy syndrome	6.44e-07	7.33e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AGT—epilepsy syndrome	6.42e-07	7.31e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—APOE—epilepsy syndrome	6.29e-07	7.16e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—POMC—epilepsy syndrome	6.17e-07	7.02e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—AKT1—epilepsy syndrome	6.1e-07	6.94e-06	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AKT1—epilepsy syndrome	5.81e-07	6.62e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT1—epilepsy syndrome	5.44e-07	6.19e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—POMC—epilepsy syndrome	5.4e-07	6.15e-06	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AKT1—epilepsy syndrome	5.06e-07	5.76e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALB—epilepsy syndrome	4.93e-07	5.61e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS2—epilepsy syndrome	4.92e-07	5.6e-06	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AKT1—epilepsy syndrome	4.55e-07	5.19e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AKT1—epilepsy syndrome	4.33e-07	4.93e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS2—epilepsy syndrome	4.31e-07	4.91e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKT1—epilepsy syndrome	4.01e-07	4.56e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKT1—epilepsy syndrome	2.47e-07	2.82e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKT1—epilepsy syndrome	2.17e-07	2.47e-06	CbGpPWpGaD
